More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/TP53 Recombinant Antibody AE00292
Cross-reactivity assessment of TP53 Mouse Recombinant Antibody AE00292 (1ug/ml) on CDI’s Protein Array containing more than 19,000 full-length human proteins.
Cross-reactivity assessment of TP53 Mouse Recombinant Antibody AE00292 (1ug/ml) on CDI’s Protein Array containing more than 19,000 full-length human proteins.
Cross-reactivity assessment of TP53 Mouse Recombinant Antibody AE00292 (1ug/ml) on CDI’s Protein Array containing more than 19,000 full-length human proteins.

TP53 Recombinant Antibody AE00292

Research Use Only
AE00292
Aeonian Biotech
TargetTP53
DownloadMSDS
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    Aeonian Biotech
  • Product Name
    TP53 Recombinant Antibody
  • Delivery Days Customer
    9
  • Applications Supplier
    IHC, PA, WB
  • Category Supplier
    Antibody
  • Certification
    Research Use Only
  • Clonality
    Recombinant
  • Clone ID
    rBP53-12
  • Conjugate
    Unconjugated
  • Gene ID7157
  • Target name
    TP53
  • Target description
    tumor protein p53
  • Target synonyms
    antigen NY-CO-13; BCC7; BMFS5; cellular tumor antigen p53; LFS1; mutant tumor protein 53; P53; p53 tumor suppressor; phosphoprotein p53; transformation-related protein 53; TRP53; tumor protein 53; tumor supressor p53
  • Host
    Mouse
  • Isotype
    IgG1 kappa
  • Protein IDP04637
  • Protein Name
    Cellular tumor antigen p53
  • Scientific Description
    TP53 Recombinant Antibody AE00292
  • Shelf life instruction
    Integrity warranted for 24 months after purchase when handled and stored according to instructions, see below.
  • Reactivity Supplier
    Human
  • Storage Instruction
    2-8°C
  • UNSPSC
    12352203

References

  • Gaspar M, Pravin J, Rodrigues L, Uhlenbroich S, Everett KL, Wollerton F, Morrow M, Tuna M, Brewis N. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement. Cancer Immunol Res. 2020 Jun;8(6):781-793. doi: 10.1158/2326-6066.CIR-19-0798. PMID: 32273279.
    Read more
  • Lakins MA, Koers A, Giambalvo R, Munoz-Olaya J, Hughes R, Goodman E, Marshall S, Wollerton F, Batey S, Gliddon D, Tuna M, Brewis N. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models. Clin Cancer Res. 2020 Aug 1;26(15):4154-4167. doi: 10.1158/1078-0432.CCR-19-2958. Epub 2020 Apr 28. PMID: 32345647.
    Read more
  • Webb ER, Lanati S, Wareham C, Easton A, Dunn SN, Inzhelevskaya T, Sadler FM, James S, Ashton-Key M, Cragg MS, Beers SA, Gray JC. Immune characterization of pre-clinical murine models of neuroblastoma. Sci Rep. 2020 Oct 7;10(1):16695. doi: 10.1038/s41598-020-73695-9. PMID: 33028899.
    Read more
  • Innamarato P, Asby S, Morse J, Mackay A, Hall M, Kidd S, Nagle L, Sarnaik AA, Pilon-Thomas S. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells. J Immunol. 2020 Nov 15;205(10):2893-2904. doi: 10.4049/jimmunol.2000759. PMID: 33020146.
    Read more
  • Song E, Mao T, Dong H, Boisserand LSB, Antila S, Bosenberg M, Alitalo K, Thomas JL, Iwasaki A. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature. 2020 Jan;577(7792):689-694. doi: 10.1038/s41586-019-1912-x. Epub 2020 Jan 15. Erratum in: Nature. 2021 Feb;590(7845):E34. PMID: 31942068.
    Read more
  • Kim B, Sun R, Oh W, Kim AMJ, Schwarz JR, Lim SO. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation. Mol Carcinog. 2020 Jul;59(7):691-700. doi: 10.1002/mc.23170. Epub 2020 Mar 1. PMID: 32115801.
    Read more
  • Salazar-Degracia A, Granado-Martínez P, Millán-Sánchez A, Tang J, Pons-Carreto A, Barreiro E. Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice. J Cell Physiol. 2019 Aug;234(10):18041-18052. doi: 10.1002/jcp.28437. PMID: 30851071.
    Read more
  • Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity. Nat Commun. 2019 May 20;10(1):2141. doi: 10.1038/s41467-019-10088-1. PMID: 31105267.